News & Events about Omega Therapeutics.
Omega Therapeutics, Inc. (NASDAQ:OMGA Get Rating) Director Richard A. Young sold 5,000 shares of the firms stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $8.00, for a total value of $40,000.00. Following the sale, the director now directly owns 749,118 ...
Omega Therapeutics (NASDAQ:OMGA Get Rating) and Biogen (NASDAQ:BIIB Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst ...
Omega Therapeutics, Inc. (NASDAQ:OMGA Get Rating) major shareholder Flagship Pioneering Inc. bought 3,323,310 shares of Omega Therapeutics stock in a transaction dated Monday, February 27th. The stock was acquired at an average cost of $5.78 per share, with a total value of $19,208,731.80. Following...
Omega Therapeutics, Inc. (NASDAQ:OMGA Get Rating) major shareholder Flagship Pioneering Inc. bought 3,323,310 shares of Omega Therapeutics stock in a transaction dated Monday, February 27th. The stock was acquired at an average cost of $5.78 per share, with a total value of $19,208,731.80. ...
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...